Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is a fast-growing cancer of the blood and bone marrow, which is the soft, spongy tissue inside your bones. It affects a specific type of immature white blood cell called promyelocytes. APL is a rare but serious condition that requires immediate treatment, though it often has a very good outlook with modern therapies.

What is Acute Promyelocytic Leukemia?

Acute promyelocytic leukemia (APL) is a rare and aggressive type of acute myeloid leukemia (AML), a cancer affecting the blood and bone marrow. It involves a specific genetic change that causes immature white blood cells, called promyelocytes, to build up and not mature properly. This buildup can lead to serious bleeding and clotting problems if not treated quickly.

APL is a cancer that starts in the bone marrow, the soft, spongy center of your bones where blood cells are made. In APL, the body produces too many immature white blood cells called promyelocytes. These cells do not develop into healthy, infection-fighting white blood cells. Instead, they accumulate in the bone marrow and blood, crowding out normal blood cells. This overgrowth of abnormal promyelocytes prevents the bone marrow from making enough healthy red blood cells, white blood cells, and platelets. Red blood cells carry oxygen, white blood cells fight infection, and platelets help blood clot. A key feature of APL is that these abnormal promyelocytes can release substances that interfere with the body's ability to clot blood, leading to a high risk of severe bleeding or unusual blood clots. APL is considered an acute leukemia because it progresses very quickly. It is a subtype of acute myeloid leukemia (AML), making up about 1 to 2 out of every 10 cases (10-15%) of AML. While serious, APL is often highly treatable, with many people achieving long-term remission thanks to specific targeted therapies. (MedlinePlus, Mayo Clinic)

Symptoms

Symptoms of acute promyelocytic leukemia (APL) often appear suddenly and are related to the lack of healthy blood cells and problems with blood clotting. Common signs include unusual bleeding or bruising, extreme tiredness, fever, and frequent infections. These symptoms require prompt medical attention to ensure a timely diagnosis and treatment.

The symptoms of APL are usually caused by a shortage of normal blood cells in the body. When there are not enough healthy red blood cells, you may experience anemia, leading to fatigue, weakness, and pale skin. A lack of normal white blood cells can make you more prone to infections, causing fevers and chills. One of the most serious symptoms of APL is related to problems with blood clotting. The abnormal promyelocytes can disrupt the body's clotting system, leading to both excessive bleeding and, less commonly, blood clots. You might notice easy bruising, frequent nosebleeds, bleeding gums, or heavy menstrual bleeding. More severe bleeding can occur internally, such as in the brain or abdomen, which can be life-threatening. Other symptoms can include shortness of breath, especially with activity, due to anemia. You might also experience unexplained weight loss or a general feeling of being unwell. Because these symptoms can be vague or similar to other conditions, it's important to see a doctor for any persistent or worsening signs. (Mayo Clinic, MedlinePlus)

Causes & risk factors

Acute promyelocytic leukemia (APL) is caused by a specific genetic change in bone marrow cells, where parts of two different chromosomes swap places. This creates an abnormal gene called PML-RARA, which stops promyelocytes from maturing. APL is not typically inherited from parents, and there are no known lifestyle or environmental risk factors that significantly increase your chance of developing it.

The underlying cause of APL is a specific genetic mutation (change) that occurs in the blood-forming cells of the bone marrow. This mutation is called a translocation, where a piece of chromosome 15 and a piece of chromosome 17 break off and switch places. This swap creates a new, abnormal gene called PML-RARA. The PML-RARA gene interferes with the normal maturation process of promyelocytes, a type of immature white blood cell. Instead of developing into healthy, mature white blood cells that fight infection, these promyelocytes remain immature and multiply uncontrollably. This genetic change is acquired during a person's lifetime and is not usually inherited from their parents. It is not passed down through families. Unlike some other cancers, APL is not strongly linked to specific lifestyle choices, environmental exposures, or family history. Most people who develop APL have no clear risk factors. The exact reason why this specific genetic change occurs in an individual is generally unknown. (MedlinePlus, Mayo Clinic)

How it's diagnosed

Diagnosing acute promyelocytic leukemia (APL) typically involves a combination of blood tests and a bone marrow biopsy. Blood tests can show abnormal cell counts, while a bone marrow biopsy allows doctors to examine the cells directly. Specialized genetic tests, such as FISH or PCR, are crucial to confirm the specific PML-RARA gene mutation, which is definitive for APL.

If you have symptoms suggesting leukemia, your doctor will likely start with a complete blood count (CBC). This blood test measures the number of red blood cells, white blood cells, and platelets. In APL, the CBC often shows low levels of healthy red blood cells and platelets, and sometimes an abnormal number of white blood cells, including the presence of immature promyelocytes. To confirm the diagnosis, a bone marrow biopsy and aspiration are usually performed. During this procedure, a small sample of liquid bone marrow (aspiration) and a tiny piece of solid bone marrow (biopsy) are taken, usually from the hip bone. These samples are then examined under a microscope by a pathologist to identify the abnormal promyelocytes and assess the overall health of the bone marrow. The most important diagnostic step for APL is to identify the specific PML-RARA gene mutation. This is done using specialized genetic tests on blood or bone marrow samples, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR). These tests can quickly and accurately detect the unique genetic change that defines APL, which is critical for guiding treatment decisions. (Mayo Clinic, MedlinePlus)

Treatment options

Treatment for acute promyelocytic leukemia (APL) focuses on specific targeted therapies that encourage the abnormal promyelocytes to mature. The primary treatments are all-trans retinoic acid (ATRA) and arsenic trioxide, often used together. These medications are highly effective and have significantly improved the outlook for people with APL, often reducing the need for traditional chemotherapy.

The cornerstone of APL treatment involves two main medications: all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA is a form of vitamin A that works by signaling the immature promyelocytes to mature into healthy white blood cells. Arsenic trioxide also helps these abnormal cells mature and eventually die off. When used together, ATRA and ATO are highly effective and have become the standard treatment for most people with APL. In some cases, especially for those with a higher risk of complications or if the initial treatment isn't fully effective, chemotherapy may be added to the treatment plan. Chemotherapy drugs work by killing fast-growing cells, including cancer cells. However, with the success of ATRA and ATO, the need for intensive chemotherapy has significantly decreased for many APL patients, reducing associated side effects. Supportive care is also a critical part of APL treatment. This includes transfusions of red blood cells or platelets to manage anemia and bleeding. Medications to prevent or treat infections are also given, as people with APL are at a higher risk due to their compromised immune system. Close monitoring for potential side effects, such as differentiation syndrome (a serious but treatable complication), is also essential throughout treatment. (Cochrane Library, Mayo Clinic, MedlinePlus)

Recovery & outlook

The outlook for acute promyelocytic leukemia (APL) has dramatically improved with modern targeted therapies, making it one of the most curable types of acute leukemia. Most people achieve long-term remission, meaning the cancer is no longer detectable. Recovery involves ongoing monitoring and managing potential side effects, but many individuals can return to a good quality of life after treatment.

With the advent of targeted therapies like all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the prognosis for APL has transformed. Before these treatments, APL was often fatal due to severe bleeding. Now, a large majority of people with APL achieve complete remission, and many go on to be cured. Studies show that a high percentage of people, often over 80-90%, achieve long-term survival without recurrence. (Cochrane Library, Mayo Clinic) After initial treatment, which typically lasts several months, ongoing monitoring is crucial. This involves regular blood tests and sometimes bone marrow biopsies to check for any signs of the leukemia returning. This follow-up period can last for several years. Early detection of recurrence allows for prompt intervention, which can improve outcomes. Recovery also involves managing any lingering side effects from treatment, such as fatigue or nerve damage. Many people can return to their normal activities and work after treatment. It's important to maintain a healthy lifestyle and attend all follow-up appointments. While the outlook is generally very positive, it's a serious condition, and continued medical care is essential for long-term health. (MedlinePlus)

When to see a doctor

You should see a doctor immediately if you experience any symptoms of acute promyelocytic leukemia (APL), especially unusual bleeding or bruising, persistent fatigue, unexplained fever, or frequent infections. Because APL can progress rapidly and cause life-threatening complications like severe bleeding, prompt medical evaluation is crucial for an accurate diagnosis and timely treatment.

If you notice any of the following symptoms, it's important to seek medical attention without delay: * **Unusual or excessive bleeding:** This includes frequent nosebleeds, bleeding gums, heavy menstrual periods, easy bruising, or red/purple spots on your skin (petechiae). * **Extreme fatigue or weakness:** Feeling unusually tired, even after rest, or having a general lack of energy. * **Persistent fever or frequent infections:** A fever without a clear cause, or getting infections more often than usual. * **Shortness of breath:** Feeling breathless, especially with mild activity, which could indicate anemia. These symptoms can be signs of APL or other serious conditions. Because APL can lead to severe bleeding complications very quickly, it is vital not to delay seeking medical help. Early diagnosis and treatment are key to a successful outcome. Always discuss any new or worsening symptoms with a qualified clinician. (Mayo Clinic, MedlinePlus)

Frequently asked questions

Is acute promyelocytic leukemia (APL) curable?

Yes, acute promyelocytic leukemia (APL) is considered one of the most curable types of acute leukemia. With modern targeted therapies, particularly the combination of all-trans retinoic acid (ATRA) and arsenic trioxide, a high percentage of people achieve long-term remission and are considered cured. (Mayo Clinic, Cochrane Library)

Is APL hereditary or genetic?

APL is caused by a specific genetic change (a translocation between chromosomes 15 and 17) that creates the PML-RARA gene. However, this genetic change is acquired during a person's lifetime in their bone marrow cells and is not typically inherited from parents. It is not considered a hereditary condition that runs in families. (MedlinePlus, Mayo Clinic)

What is the difference between APL and other types of leukemia?

APL is a specific subtype of acute myeloid leukemia (AML). What makes APL unique is the specific genetic mutation (PML-RARA) and its characteristic response to targeted therapies like ATRA and arsenic trioxide. This makes its treatment and prognosis distinct from other forms of AML and other types of leukemia, such as acute lymphoblastic leukemia (ALL) or chronic leukemias. (MedlinePlus, Mayo Clinic)

How long does treatment for APL usually last?

The initial phase of APL treatment, which aims to achieve remission, typically lasts several weeks. After this, people usually undergo a consolidation phase, which can last for several months, to eliminate any remaining leukemia cells. Some individuals may then have a maintenance phase, which can extend for one to two years, though the exact duration varies based on individual risk factors and treatment protocols. (Mayo Clinic)

What are the common side effects of APL treatment?

Common side effects of APL treatment, particularly with ATRA and arsenic trioxide, can include headache, fatigue, skin dryness, and nausea. A specific and serious side effect is differentiation syndrome, which can cause fever, fluid retention, breathing difficulties, and low blood pressure. This syndrome requires immediate medical attention but is treatable. Your care team will monitor you closely for these and other potential side effects. (MedlinePlus, Mayo Clinic)

Can APL come back after treatment?

While the cure rates for APL are very high, there is always a small risk that the leukemia could return (recur). This is why regular follow-up appointments and monitoring tests, such as blood tests and sometimes bone marrow biopsies, are crucial after treatment. If APL does recur, it can often be successfully treated again. (Mayo Clinic)

Sources

• MedlinePlus — Acute Promyelocytic Leukemia
• Mayo Clinic — Acute Promyelocytic Leukemia
• Cochrane Library — Acute Promyelocytic Leukemia